STC-1020 / Brenus Pharma - LARVOL DELTA

Brenus Pharma Raises $25 Million to Accelerate Clinical Trials of Its Precision Cancer Vaccines. (Businesswire) - "Brenus Pharma...announces the completion of a $25 million Series A financing round...The Series A round, led by a group of French investors in association with Belgian investment funds, will be used to finance the first Phase I/IIA clinical trial of Brenus’ first candidate, STC-1010, in metastatic colorectal cancer, as well as the development of a second candidate in another solid tumor indication (STC-1020)...Brenus Pharma will meet this high unmet need thanks to its innovation from end of 2024 with its first clinical trial in France, Belgium and the USA."

Financing • New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor